Medical Advocates
Darunavir (Prezista/TMC-114)
  Main Page

New and Noteworthy
Product Information
Protease Inhibitors: General Data
 Journal Data
 Conference Data
Pediatric Data
Perinatal  Data



 		  
ARV Drugs Main Page Drugs Main Page          Main New/Newsworthy  Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  February 04, 2012 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
January 2012
 
Product Information
     
  • FULL-TEXT PDF DOCUMENT
    Prezista PI
    June 25, 2006
    Document
Pediatric Data
     
USPHS Pediatric Antiretroviral Drug Information
US Treatment Guidelines
 
Journal  Abstracts, Papers and Commentaries
 
 
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
Donegan KL, Walker AS, Dunn D,
Antivir Ther. 2011 Dec 15.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced
children and adolescents
Blanche S, Bologna R, Cahn P, et al 
AIDS. 2009 Aug 30
 Abstract

FULL-TEXT ARTICLE
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M, Kovacs A.
 Ther Clin Risk Manag. 2009 Jun;5(3):595-615.
Paper

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M, Kovacs A.
 Ther Clin Risk Manag. 2009 Jun;5(3):595-615
 Abstract

Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child
with vertically acquired multidrug-resistant HIV-1.
Viganò A, Meroni L, Marchetti G, et al
Antivir Ther. 2008;13(6):839-43.
Abstract
 
Conference Reports, Abstracts and Posters
 
 
POSTER
 Pharmacokinetics of DRV/r in Asian HIV-1+ 6-Year-old Children
K Chokephaibulkit, W Prasitsuebsai, O Wittawatmongkol, et al
 (18 CROI)
 PDF Poster     Abstract

48-week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced,
paediatric patients in DELPHI
T. Meyers, E. Joao, J.H. Pilotto,  et a
(5th IAS Conference)
Abstract

Safety and Efficacy of Darunavir Co-administered with Low-dose Ritonavir in Treatment-experienced
Children and Adolescents at Week 24
 R Bologna, S Rugina, P Cahn, et al
 (15th CROI)
Abstract
 
Dose selection of darunavir co-administered with low-dose ritonavir (DRV/r) in
treatment-experienced HIV-1-infected children and adolescents
 Spinosa-Guzman S, Sekar VJ, Van Baelen B, et al
 (4th IAS Conference)
Abstract

Salvage therapy in perinatally acquired HIV infection: first UK experience of TMC114
 A Bamford, C Foster, NE Mackie, et al|
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
Perinatal Data
       
Guidelines
 
     United States

          Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
          Journal  Abstracts, Papers and Commentaries
 
  Use of darunavir and enfuvirtide in a pregnant woman.
 Sued O, Lattner J, Gun A, et al
Int J STD AIDS. 2008 Dec;19(12):866-7.
 Abstract

ARV Drugs Main Page Drugs Main Page               Main New/Newsworthy  Home Page      

Darunavir (Prezista/TMC114)